公开(公告)号：EP3202759A1

公开(公告)日：2017-08-09

申请号：EP15847985.7

申请日：2015-09-24

Applicant: Korea Institute of Science and Technology

Inventor： PARK, Ki Duk ,  LEE, Changjoon Justin ,  KIM, Dong Jin ,  PAE, Ae Nim ,  CHOO, Hyun Ah ,  MIN, Sun Joon ,  KANG, Yong Koo ,  KIM, Yun Kyung ,  SONG, Hyo Jung ,  CHOI, Ji Won ,  NAM, Min Ho ,  HEO, Jun Young ,  YEON, Seul Ki ,  JANG, Bo Ko ,  JU, Eun Ji ,  JO, Seon Mi ,  PARK, Jong-Hyun

IPC: C07C237/20 ,  C07C237/04 ,  C07C231/12 ,  C07C309/04 ,  A61K31/16 ,  A61K31/167

Abstract: The present disclosure relates to an α-aminoamide derivative compound and a pharmaceutical composition containing the same. According to various embodiments of the present disclosure, provided is a therapeutic agent which can overcome the disadvantages of existing drugs used as a MAO-B inhibitor and, specifically, reversibly inhibits MAO-B through a non-covalent bond so as to alleviate or eliminate the side effects of the existing drugs which exhibit a therapeutic effect by irreversibly acting via a covalent bond with MAO-B. Particularly, a new compound having superior stability and efficacy compared to the existing reversible MAO-B inhibitors may be provided.

Abstract translation: 本公开涉及α-氨基酰胺衍生物化合物和含有其的药物组合物。 根据本公开的各种实施方式，提供了一种治疗剂，其可以克服现有药物用作MAO-B抑制剂的缺点，并且具体地通过非共价键可逆地抑制MAO-B，从而缓解或消除 现有药物通过与MAO-B通过共价键发挥不可逆作用而表现出治疗效果的副作用。 特别地，可以提供与现有可逆MAO-B抑制剂相比具有优良稳定性和功效的新化合物。

公开(公告)号：EP3013346A1

公开(公告)日：2016-05-04

申请号：EP14817212.5

申请日：2014-06-26

Applicant: Korea Institute of Science and Technology

Inventor： KIM, Dong Jin ,  KIM, Young Soo ,  KIM, Hye Yun ,  KIM, Hyun Jin

IPC: A61K31/5375 ,  A61K31/4965 ,  A61K31/445 ,  A61P25/16

CPC classification number: C07D295/15 ,  A61K31/495 ,  A61K31/5375 ,  C07D295/088

Abstract: Provided is a pharmaceutical composition for preventing or treating a cognitive impairment-related disease, the pharmaceutical composition including N-(2-hydroxyethyl)piperazine-N'(3-propane sulfonic acid), a pharmaceutically acceptable salt thereof or a derivative thereof, and donepezil, a pharmaceutically acceptable salt thereof or a derivative thereof. The composition may be used in preventing or treating a cognitive impairment-related disease.

公开(公告)号：EP1023294B1

公开(公告)日：2003-02-12

申请号：EP98941881.9

申请日：1998-08-21

Applicant: Korea Institute of Science and Technology ,  Il Hwa Co., Ltd.

Inventor： PARK, Sang Woo ,  KIM, Dong Jin ,  SHIN, Kye Jung ,  KAGN, Yong Koo ,  KIM, Yong Zu ,  CHUNG, Yong Ho ,  LEE, Hong Woo ,  HUH, Jae Doo ,  LEE, Sang Joo ,  SUH, Il Hong ,  KO, Bong Suk

IPC: C07D477/20 ,  A61K31/40

CPC classification number: C07D477/20 ,  C07D207/16 ,  Y02P20/55

Abstract: The present invention relates to carbapenem derivatives represented by formula (I) and a preparation method thereof. The preparation method comprises first preparing the carbapenem intermediate represented by formula (VII) by reacting the carbapenem nucleus of formula (II) with diphenylchlorophosphate or trifluoromethanesulfonic anhydride in the presence of a base. Then the carbapenem intermediate represented by formula (VII) is reacted with a thiol derivative represented by formula (III) to produce the carbapenem derivatives represented by formula (I). The carbapenem derivatives represented by formula (I) of the present invention have excellent antibacterial properties and thus can be used as antibiotics.

公开(公告)号：EP3305070B1

公开(公告)日：2020-07-22

申请号：EP17195792.1

申请日：2017-10-10

Applicant: Korea Institute of Science and Technology

Inventor： KIM, Do Hee ,  SHIN, Seul Gi ,  LIM, Sung Su ,  PAE, Ae Nim ,  KIM, Dong Jin ,  KIM, Yun Kyung

IPC: A01K67/027 ,  C12N15/85 ,  G01N33/50 ,  C12N5/073 ,  G01N33/68

公开(公告)号：EP3305070A1

公开(公告)日：2018-04-11

申请号：EP17195792.1

申请日：2017-10-10

Applicant: Korea Institute of Science and Technology

Inventor： KIM, Do Hee ,  SHIN, Seul Gi ,  LIM, Sung Su ,  PAE, Ae Nim ,  KIM, Dong Jin ,  KIM, Yun Kyung

IPC: A01K67/027 ,  C12N15/85 ,  G01N33/50 ,  C12N5/073

Abstract: The present invention relates to a vector pair for screening tau oligomer formation, a mouse embryo introduced with the vector pair, a transgenic model mouse of neurological disease, obtained from the mouse embryo, and a method of screening a tau oligomer formation inhibitor candidate using the transgenic model mouse. More specifically, the present invention provides vector pair for screening tau oligomer formation, comprising: a first vector comprising a first tau gene, a first fluorescence protein gene and a first neuron-specific promoter; and a second vector comprising a second tau gene, a second fluorescence protein gene and a second neuron-specific promoter, wherein a protein expressed from the first fluorescence protein gene and a protein expressed from the second fluorescence protein gene bind to each other to display fluorescence, by association between a protein expressed from the first tau gene and a protein expressed from the second tau gene.

Abstract translation: 本发明涉及用于筛选tau寡聚体形成的载体对，从载体对引入的小鼠胚胎，从小鼠胚胎获得的神经疾病的转基因模型小鼠，以及使用该载体对筛选τ寡聚物形成抑制剂候选物的方法 转基因模型小鼠。 更具体地，本发明提供了用于筛选tau寡聚体形成的载体对，其包含：第一载体，其包含第一tau基因，第一荧光蛋白基因和第一神经元特异性启动子; 以及第二载体，其包含第二tau基因，第二荧光蛋白基因和第二神经元特异性启动子，其中从第一荧光蛋白基因表达的蛋白和从第二荧光蛋白基因表达的蛋白相互结合以显示荧光 通过从第一个tau基因表达的蛋白质和从第二个tau基因表达的蛋白质之间的结合来实现。

公开(公告)号：EP2990801A1

公开(公告)日：2016-03-02

申请号：EP14788047.0

申请日：2014-04-25

Applicant: Korea Institute of Science and Technology

Inventor： KIM, Young Soo ,  KIM, Dong Jin ,  KIM, Hye Yun ,  CHO, Soo Min ,  LEE, Sejin ,  KIM, Hyunjin ,  KIM, Tae Song ,  HWANG, Kyoseon ,  ROH, Jee Hoon ,  KOH, Jae-Young

IPC: G01N33/68 ,  G01N33/53

CPC classification number: G01N33/6893 ,  A61K38/1716 ,  C07K14/4711 ,  G01N33/6827 ,  G01N33/6896 ,  G01N2333/4709 ,  G01N2800/2821

Abstract: The present disclosure relates to a diagnostic kit capable of accurately diagnosing diseases or disorders related with abnormal aggregation or misfolding of proteins, including disorders or diseases caused by aggregation of β-amyloid such as Alzheimer's disease as well as disorders or diseases caused by aggregation of other proteins, based on concentration analysis of the aggregated proteins before and after dissociation.

Abstract translation: 本发明涉及一种能够精确地设定诊断与异常聚集或蛋白质的错误折叠，包括²淀粉样蛋白的聚集引起的病症或疾病相关的疾病或病症的诊断试剂盒：如阿尔茨海默氏病，以及由其他聚合引起的病症或疾病 蛋白质的基础上，前和后解离的聚集的蛋白的浓度分析。